Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-emption Defense: Pharma Must Show Record Of Interaction With FDA

Executive Summary

The Supreme Court's ruling in Wyeth v. Levine, which limits the circumstances in which companies can claim FDA-approved labeling pre-empts state product liability suits, is going to require companies to have a detailed dialogue with FDA

You may also be interested in...



Roche Gets Second Chance In Accutane Liability Suit; Pre-emption Still Possible

A New Jersey appeals court vacated a $2.6 million jury verdict against Roche and ordered a new trial to determine if its acne drug Accutane (isotretinoin) caused a plaintiff's inflammatory bowel disease

Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk

While the Supreme Court's landmark ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from product liability lawsuits, it will not trigger any sea change in litigation. Instead, the opinion seems likely to maintain the status quo and restrict the situations in which companies can claim they provided adequate warning of a drug's risks

Rx Injury Claims May Grow After Court Finds Brand Liable For Generic Problems

The pharmaceutical industry is reeling from a court ruling that found brand name manufacturers are liable for the warnings on generic versions of their products

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel